(250) NanoPULSE: The First Micromixer Method Delivering Consistent Lipid Nanoparticle Across All Scales
Introduction: The development of RNA-based vaccines and therapies using lipid nanoparticle (LNP) formulations is currently hindered by the lack of unifiedformulation technology that covers the entire drug development pipeline. Transitions between formulation methods, like microfluidics and impingement jet mixing, affect LNP CQAs consistency hence making scale-up difficult. [1] This results in slow, costly, and sometimes unsuccessful drug development. Here, we introduce NanoPULSE, a novel, patented microfluidic-based active micromixer that ensures consistent LNP characteristics across all production volumes
Learning Objectives:
Identify challenges in scaling RNA-LNP formulations from µL screening to large-scale production
Explore how NanoPULSE delivers a unified, consistent approach to LNP production across scales.
Evaluate the role of numerical simulations and experiments in optimizing and validating NanoPULSE.
